Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1141148
Abstract: Background Whether irAEs can predict the efficacy of PD-1 inhibitors in cholangiocarcinoma (CCA) has not been assessed. Therefore, this study aims to investigate the correlation between irAEs and the therapeutic effect of PD-1 inhibitors combination… read more here.
Keywords: non iraes; inhibitors combination; cohort; combination therapy ... See more keywords
Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29050238
Abstract: In this study, we aimed to evaluate the efficacy of PD-1 inhibitors in combination with concurrent CRT/CT for patients with inoperable ESCC in the real world and to find predictors for the efficacy of PD-1… read more here.
Keywords: combination chemoradiotherapy; efficacy inhibitors; chemoradiotherapy chemotherapy; inhibitors combination ... See more keywords
Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus
Sign Up to like & getrecommendations! Published in 2018 at "Indian Journal of Endocrinology and Metabolism"
DOI: 10.4103/ijem.ijem_162_17
Abstract: Involvement of multiple physiological pathways and complex pathogenesis is responsible for the onset and progression of type 2 diabetes mellitus (T2DM). Since it is difficult to manage multiple pathophysiological defects by monotherapy, a combination therapy… read more here.
Keywords: combination; sglt2 inhibitors; sodium glucose; inhibitors combination ... See more keywords